Bibliographic record
Abstract
Canadian specialty pharmaceutical firm Biovail will buy Valeant Pharmaceuticals of Aliso Viejo, Calif., in a complex stock deal valued at about $3.3 billion. The transaction will create a company, to be called Valeant Pharmaceuticals, with combined annual revenues of about $1.75 billion. The firm will specialize in central nervous system therapies, dermatology treatments, and generic drugs, with a focus on Canada and emerging markets. Current Valeant CEO J. Michael Pearson will head the combined company, which will be based in Mississauga, Ontario. The deal significantly expands Biovail’s drug portfolio beyond its current concentration on extended-release technology and central nervous system therapies. The Canadian firm’s products include Wellbutrin XL, an extended-release antidepressant acquired from GlaxoSmithKline, and Ultram ER, an extended-release pain therapy. Valeant markets a number of products in dermatology and neurology and manufactures branded generics. In recent years, Biovail has operated under the shadow of accounting scandals, including allegations that the firm manipulated financial results ...
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.002 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.003 | 0.000 |
| Scholarly communication | 0.003 | 0.001 |
| Open science | 0.000 | 0.001 |
| Research integrity | 0.002 | 0.002 |
| Insufficient payload (model declined to judge) | 0.138 | 0.034 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".